Karen Keough
Epilepsy · Austin, TXNPI 1538147707
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $358,773 of the $473,964 with a category attached, or 75.7%. 49 manufacturers reported payments, led by Jazz Pharmaceuticals Inc. at 31.2% of the total. Among epilepsy clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,102 payments — averaging $430.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Jazz Pharmaceuticals Inc.$148K
- SK Life Science, Inc.$96K
- UCB, Inc.$70K
- Greenwich Biosciences, Inc.$65K
- Livanova USA, Inc.$58K
- Biocodex, Inc.$10K
- plus $27K from 43 others
Across 159 payments — averaging $3780.97 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eisai Inc.$170K
- Livanova USA, Inc.$164K
- Immedica Pharma US, Inc.$115K
- SK Life Science, Inc.$57K
- UCB SA$53K
- H. Lundbeck A S$25K
- plus $16K from 1 others
What the payments were for
- Consulting fees$44,3149%
- Speaking & faculty fees$358,77376%
- Travel & lodging$48,91810%
- Food & beverage$21,4925%
- Education$4670%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Epidiolex$209,093
- XCOPRI$90,326
- Fintepla$79,111
- VNS THERAPY SENTIVA MODEL 1000 GENERATOR$31,156
- VNS Therapy$18,215
- DIACOMIT$9,676
- VNS - Sentiva$6,275
- SYMPAZAN$2,178
- RNS Neurostimulator Kit$482
- DAYBUE$200
- Brineura$109
How this compares
$473,964 in reported general payments places this provider in the 95th percentile of 36 epilepsy providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AfinitorEverolimus | 14 | $262,130 |
| EpidiolexCannabidiol (Cbd) | 24 | $132,567 |
| XcopriCenobamate | 68 | $72,167 |
| Clobazam | 41 | $9,141 |
| Lamotrigine ErLamotrigine | 21 | $7,823 |
| Everolimus | 24 | $6,795 |
| Felbamate | 11 | $2,514 |
| Diazepam | 15 | $667 |
| Olanzapine OdtOlanzapine | 12 | $369 |
| Risperidone | 12 | $144 |
| Trazodone Hcl | 12 | $59 |
| Fluoxetine Hcl | 13 | $36 |
| Omeprazole | 13 | $14 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisAfinitor | $34 | $262,13014 claims |
| SK Life Science, Inc.Xcopri | $96,367 | $72,16768 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 36 epilepsy providers in Texas.
Other epilepsy in Austin
- Katherine LabinerAustin$163K
- Daniel GustkeyAustin$12K
- Andrew LinAustin$42
- Jay HarveyDallas$19K
- Charles SzaboSan Antonio$15K
- Erin FiedlerDallas$9K
- Linda LearySan Antonio$9K
- Leonel EstofanEdinburg$9K
- Bernhard SuterHouston$6K
- Irfan AliHouston$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.